Anda di halaman 1dari 2

Neuroprotective Products: World Market Prospects 2012-2022

worth $2-4bn and novel treatments for slow down the progression of injury are much in demand. This will ensure that NeuroSTAT gains market share, considering its neuroprotective benefits.

4.5 Erythropoietin (Various Companies)

Erythropoietin (EPO) is approved as a treatment of anaemia due to a number of conditions. EPO is involved in modulating a variety of cellular processes including progenitor stem cell development. The role of EPO in neuroprotection is well appreciated in the scientific community and EPO is currently under investigation as a neuroprotectant in several clinical trials. These studies are summarised in the following table.

Table 4.7 Studies Investigating Erythropoietin as a Neuroprotectant, 2012

Indication Congenital Heart Disease/ Hypoplastic Left Heart Syndrome/ Transposition of the Great Arteries/ Aortic Arch Hypoplasia or Interruption Phase I/II Completion Sep 2016 Organisations Baylor College of Medicine/ Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/ The Dana Foundation/ Texas Children's Hospital Extreme Prematurity Infant, Premature/Leukomalacia, Periventricular/ Intraventricular II/III I/II Dec 2017 July 2011 University of Washington/ NINDS China Medical University Hospital

Haemorrhage/Retinopathy of Prematurity Hypoxic-ischemic Encephalopathy I Dec 2012 University of California, San Francisco/ Thrasher Research Fund/ Children's Hospital & Research Center Oakland/ University of Washington/ Santa Clara Valley Health & Hospital System Hypoxic Ischemic Encephalopathy Source: visiongain 2012 I/II March 2014 University of Utah

4.5.1 EPO: Competitor Analysis and Sales Forecast, 2012-2022

EPO has shown promising results in nearly all the clinical trials testing its neuroprotective effects. All major clinical trials testing neuroprotective effects of EPO are expected to be completed only

Page 51

Neuroprotective Products: World Market Prospects 2012-2022

after 2015. Therefore, the sales of EPO prior to 2015 do not necessarily reflect its neuroprotective potential. By 2016, the annual growth rate of erythropoietin sales will increase because several clinical trials will conclude around this time. However, exactly when EPO will begin to be marketed exclusively as a neuroprotectant is unclear.

Table 4.8 Erythropoietin Sales Forecast ($bn), 2011-2022

Erythropoietin ($bn) Annual Growth (%) CAGR (% from 2011)
Source: visiongain 2012

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04 0.05 0.07 0.10 4.00 4.00 7.00 8.00 10.00 14.00 20.00 20.00 35.00 35.00 40.00 6.57 17.25

Figure 4.5 Erythropoietin Sales Forecast ($bn), 2011-2022

Source: visiongain 2012

Page 52